Last reviewed · How we verify
Sirolimus + Maraviroc
This combination uses sirolimus (an mTOR inhibitor) to suppress immune cell proliferation and maraviroc (a CCR5 antagonist) to block HIV entry, together targeting both viral replication and immune dysregulation.
This combination uses sirolimus (an mTOR inhibitor) to suppress immune cell proliferation and maraviroc (a CCR5 antagonist) to block HIV entry, together targeting both viral replication and immune dysregulation. Used for HIV-1 infection (R5-tropic virus).
At a glance
| Generic name | Sirolimus + Maraviroc |
|---|---|
| Also known as | Rapamycin, Rapamune, Selzentry |
| Sponsor | University of Maryland, Baltimore |
| Drug class | mTOR inhibitor + CCR5 antagonist combination |
| Target | mTOR; CCR5 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease (HIV) |
| Phase | FDA-approved |
Mechanism of action
Sirolimus inhibits the mTOR pathway, reducing T-cell and B-cell proliferation and promoting regulatory T-cell differentiation. Maraviroc blocks the CCR5 chemokine receptor on CD4+ T cells, preventing R5-tropic HIV entry. Together, they aim to reduce viral load while modulating immune activation in HIV-infected patients.
Approved indications
- HIV-1 infection (R5-tropic virus)
Common side effects
- Immunosuppression
- Diarrhea
- Elevated liver enzymes
- Hyperlipidemia
- Cough
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sirolimus + Maraviroc CI brief — competitive landscape report
- Sirolimus + Maraviroc updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI